Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpineJack trial results lead to European launch

This article was originally published in Clinica

Executive Summary

The European launch of SpineJack, Vexim's vertebral implant, is expected "within the next few weeks" following positive clinical trial results. The titanium implant, designed for minimally-invasive anatomical restoration of vertebral compression fractures, has been proven efficacious in two clinical studies in a total of 120 patients. Following implantation of the SpineJack, all patients experienced rapid pain relief and correction of post-trauma deformation, assessed by methods including conventional radiography and CT scanning. Vexim (Toulouse, France) CE marked SpineJack in May 2008, but decided to market it only after demonstrating its efficacy in international clinical trials. SpineJack is inserted into a patient's vertebra via a transpedicular approach, involving the X-ray-guided insertion of one or two implants, depending on the anatomical configuration of the fracture and the degree of reconstruction required. The company is planning to conduct further clinical studies of SpineJack this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel